Healthcare / BiotechnologyKOSDAQ
$6470.00
-440.00 (-6.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-43.8M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$33.9B
P/E
56.3x
↑EV/EBITDA
14.8x
↑ROE
2.3%
↑Gross Margin
48.0%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+7.1%
FCF CAGR
—
FCF margin
-35.8%
FCF / Net income
-11.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.71B · net income $555.4M · FCF $-6.34B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $17.71B | $17.71B | $16.80B | $15.43B |
| Net Income | $555.4M | $555.4M | $-5.95B | $2.10B |
| EBITDA | $2.11B | $2.11B | $-2.66B | $5.21B |
| EPS | 115.00 | 115.00 | -1872.00 | 125.00 |
| Gross Margin | 48.0% | 48.0% | 46.9% | 44.1% |
| Operating Margin | 2.2% | 2.2% | 10.1% | 4.6% |
| Net Margin | 3.1% | 3.1% | -35.4% | 13.6% |
| Balance Sheet | ||||
| Debt/Equity | 0.32 | 0.32 | 0.64 | -5.76 |
| Current Ratio | 4.78 | 4.78 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-6.34B | $-6.34B | $-43.8M | $1.59B |
| Returns | ||||
| ROE | 2.3% | 2.3% | -54.6% | -180.7% |
| Valuation | ||||
| P/E | 56.26 | 56.26 | — | 41.60 |
| EV/EBITDA | 14.82 | 14.82 | — | 17.81 |
| P/B | 1.31 | 1.31 | 4.08 | — |
| Growth & Yield | ||||
| Revenue Growth | 5.4% | 5.4% | 8.9% | — |
| EPS Growth | 106.1% | 106.1% | -1597.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
70.9%
EPS terminal req.
$574.10
Spread vs growth
35.2%
5Y implied EPS CAGR
43.3%
EPS terminal req.
$694.67
Spread vs growth
62.9%
10Y implied EPS CAGR
25.5%
EPS terminal req.
$1118.77
Spread vs growth
80.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1872.00 → 115.00
Residual
-61.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.